Aquaretic effects of niravoline, a κ-opioid agonist, in patients with cirrhosis

This publication has 12 references indexed in Scilit:

• Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis
  Journal of Gastroenterology and Hepatology, 1996
• Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention
  Gastroenterology, 1995
• Diuretic Effects, Pharmacokinetics, and Safety of a New Centrally Acting Kappa‐Opioid Agonist (CI‐977) in Humans
  The Journal of Clinical Pharmacology, 1994
• Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats
  Kidney International, 1994
• Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites
  Seminars in Liver Disease, 1994
• Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
  Journal of Clinical Investigation, 1993
• Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V₂ receptor antagonist
  British Journal of Pharmacology, 1992
• Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites
  Gastroenterology, 1988
• Derangements of renal water handling in liver disease
  Gastroenterology, 1985
• Potential Role of Increased Sympathetic Activity in Impaired Sodium and Water Excretion in Cirrhosis
  New England Journal of Medicine, 1982